Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis

被引：0
|
作者：
Duparc, Helene
Muller, Delphine
Antony-Debre, Ileana
Marty, Caroline
Debili, Najet
Villeval, Jean-Luc
Plo, Isabelle
Vainchenker, William
Gilles, Laure
Raslova, Hana
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141092
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CDK4/6 inhibitor palbociclib reduces inflammation in lupus-prone mice
    Zhang, Yongfeng
    Jin, Ben
    Miller, Haiyan D.
    Ge, Dongxia
    Zhang, Xin
    You, Zongbing
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2021, 9 (01): : 32 - 43
  • [22] CDK4/6抑制剂palbociclib专利技术分析
    蒋薇薇
    药学研究, 2019, 38 (10) : 608 - 614
  • [23] Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
    Lin Zhu
    Qin Yang
    Rong Hu
    Yanan Li
    Yuanliang Peng
    Hong Liu
    Mao Ye
    Bin Zhang
    Peihe Zhang
    Feng Liu-Smith
    Hui Li
    Jing Liu
    Scientific Reports, 12
  • [24] Palbociclib, a CDK4/6 inhibitor, suppresses proliferation of triple negative breast cancer
    Min, Ahrum
    Kim, Yu Jin
    Hang, Hyemin
    Lim, Jee Min
    Kim, Seongyeong
    Kim, So Hyeon
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [25] A DNA-methylation signature to predict resistance to the CDK4/6 inhibitor palbociclib
    Benelli, Matteo
    Bonechi, Martina
    Romagnoli, Dario
    Biagioni, Chiara
    Migliaccio, Ilenia
    De Luca, Francesca
    Galardi, Francesca
    Di Leo, Angelo
    Malorni, Luca
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
    Zhu, Lin
    Yang, Qin
    Hu, Rong
    Li, Yanan
    Peng, Yuanliang
    Liu, Hong
    Ye, Mao
    Zhang, Bin
    Zhang, Peihe
    Liu-Smith, Feng
    Li, Hui
    Liu, Jing
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [27] CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
    Laderian, Bahar
    Fojo, Tito
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 395 - 403
  • [28] Regression of a nonfunctioning pituitary macroadenoma on the CDK4/6 inhibitor palbociclib: case report
    Anderson, Emily
    Heller, Robert S.
    Lechan, Ronald M.
    Heilman, Carl B.
    NEUROSURGICAL FOCUS, 2018, 44 (06)
  • [29] Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
    Sorrentino, J.
    Bisi, J.
    Thompson, D.
    Lai, A.
    Strum, J.
    Roberts, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E47 - E48
  • [30] Determinants of CDK4 target engagement by palbociclib, ribociclib and abemaciclib
    Green, Jennifer L.
    Nomanbhoy, Tyzoon
    CANCER RESEARCH, 2018, 78 (13)
12345